Rituximab and lenalidomide combination therapy shows promise for relapsed/refractory indolent non-Hodgkin lymphoma, with high response and remission rates. The AUGMENT trial demonstrated favorable ...
FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...
Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4). This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results